Wang Dongdong, Yin Huijia, Li Xiaoming, Zhou Shuwei, Wang Yuan-Cheng
Department of Radiology, Zhengzhou People's Hospital and The Fifth Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou, People's Republic of China.
Department of MR, The First Affiliated Hospital of Xinxiang Medical University, Weihui, People's Republic of China.
J Hepatocell Carcinoma. 2025 Aug 6;12:1743-1753. doi: 10.2147/JHC.S524533. eCollection 2025.
To investigate the application of imaging biomarkers, including R2*, Fat Fraction (FF) and apparent diffusion coefficient (ADC) values, obtained through Iterative Decomposition of water and fat with Echo Asymmetry and Least-squares estimation for Imaging Quantification (IDEAL-IQ) and DWI techniques, in differentiating P53-mutated and non-mutated HCC.
This retrospective study included patients with pathologically confirmed HCC between January 2019 and July 2024. HCC were divided into P53-mutated group and non-mutated group by immunostaining. Preoperative R2*, FF, and ADC values derived from IDEAL-IQ and DWI were compared between the two groups, as well as different histological grades. Receiver operating characteristic (ROC) analysis was used to evaluate the diagnostic performance of each MRI parameter for detecting P53 mutations in HCC, with area under the curve (AUC) compared by Delong's test.
Compared to the non-mutated group, the P53-mutated group (n = 31) showed significantly higher R2* values (34.821 ± 9.980 vs 23.713 ± 5.586, P < 0.001) and lower ADC values (0.760 ± 0.142 vs 0.855 ± 0.130, P = 0.002), while FF values showed no significant difference (P = 0.646). R2*, ADC, and the combined model (R2* + ADC) revealed AUCs of 0.849, 0.726, and 0.856, respectively, with the combined model demonstrating the highest sensitivity and specificity. Additionally, high-grade HCC showed significantly lower ADC values compared to lower-grade tumors (P < 0.001).
R2* and ADC exhibited significant features in P53-mutated HCC, suggesting their potential as non-invasive biomarkers for predicting P53 mutation status and guiding clinical management. The combined use of R2* and ADC may further enhance diagnostic accuracy.
探讨通过迭代分解水与脂肪的回波不对称和最小二乘估计成像定量(IDEAL-IQ)及扩散加权成像(DWI)技术获得的成像生物标志物,包括R2*、脂肪分数(FF)和表观扩散系数(ADC)值,在鉴别P53突变型和非突变型肝细胞癌(HCC)中的应用。
本回顾性研究纳入了2019年1月至2024年7月间经病理证实的HCC患者。通过免疫染色将HCC分为P53突变组和非突变组。比较两组以及不同组织学分级之间术前从IDEAL-IQ和DWI获得的R2*、FF和ADC值。采用受试者操作特征(ROC)分析评估每个MRI参数检测HCC中P53突变的诊断性能,通过德龙检验比较曲线下面积(AUC)。
与非突变组相比,P53突变组(n = 31)的R2值显著更高(34.821±9.980对23.713±5.586,P < 0.001),ADC值更低(0.760±0.142对0.855±0.130,P = 0.002),而FF值无显著差异(P = 0.646)。R2、ADC以及联合模型(R2* + ADC)的AUC分别为0.849、0.726和0.856,联合模型显示出最高的敏感性和特异性。此外,高级别HCC的ADC值显著低于低级别肿瘤(P < 0.001)。
R2和ADC在P53突变型HCC中表现出显著特征,表明它们作为预测P53突变状态和指导临床管理的非侵入性生物标志物的潜力。R2和ADC的联合使用可能进一步提高诊断准确性。